The Second Set of Rockets

Educational only. Not investment advice and not medical advice. I am not a registered investment adviser, broker, or physician. Everything here is my own opinion and analysis, it is speculative, and biotech carries total-loss risk. Trials fail, tests fail, and small clinical-stage companies fail often. Scoring reflects my own judgment, not objective truth. Valuations are approximate and must be independently verified. Private placements are restricted to accredited investors and carry illiquidity and total-loss risk. Conflict disclosure: I hold personal equity in Yuva Biosciences and Repair Biotechnologies, neither related to the companies in this issue. I may hold positions in securities discussed and will disclose where applicable. Do nothing here without your own physician and your own due diligence.

In 2008, one rocket stood between Elon Musk and bankruptcy.

SpaceX had launched three times. All three failed. There was money for exactly one more attempt, and on the fourth try, in September 2008, Falcon 1 finally reached orbit. If it had not, there is no Falcon 9, no Dragon, no Starlink, no trillion-dollar company. The entire fortune balanced on one launch.

But here is the part almost everyone misses. SpaceX did not win because of one rocket. It won because several forces lined up at once: Falcon 1 proved the team could reach orbit, NASA needed commercial cargo capacity after the Shuttle era, and SpaceX had built a lean engineering culture around its larger Falcon 9 and Dragon strategy. None of those was the fortune by itself. The fortune was the alignment, a handful of unglamorous pieces clicking into place at the same time, while everyone else was watching the explosions.

I have spent two+ years convinced that longevity biotech is sitting in front of that exact moment, and that almost nobody is positioned, because the pieces moving first look unbearably boring.

This letter is about the most boring piece of all. An organ you have not thought about once this week, that is quietly setting the clock on how long you live. And it is about five kidney-focused companies now on my research tracker, evaluated through my 25-Gate framework, because for the first time, the pieces are clicking.

I am 53. I approach investing and health decisions as though living to 120 is possible. That is not a slogan, it is the lens I run every company through. I do not ask "is this a good stock." I ask a harder question, and it is the rule this whole publication is built on:

I only study a company if it can, in time, offer both health relevance and investment potential. Both. Not one.

Most newsletters fail that test on purpose. They sell you a thrilling stock that does nothing for your health, or health advice you cannot act on. I refuse to blur them. A name has to clear two gates: the mechanism has to plausibly support healthier aging biology in a healthy person, and it has to be something a person could genuinely back. Pass only one, and it does not go on my tracker.

So when I tell you your kidneys are the problem, understand that I am talking about mine too.

Here is the sentence that rearranged how I think about my own body.

A blood marker called cystatin C has been associated with increased mortality risk in multiple studies. Not just kidney disease risk, all-cause mortality risk. And the association can appear even in people who do not have diagnosed kidney disease yet. People whose last physical came back clean. People who feel completely fine.

Now think about your last physical. It almost certainly measured your kidneys with a test called creatinine. Creatinine is useful, but it is influenced by muscle mass, diet, and other factors, and in people with unusually high or low muscle mass it can mislead in either direction. Cystatin C gives a second view, because it is much less dependent on skeletal muscle. The better signal is not any one number, it is the trend across creatinine, cystatin C, and urine albumin over time, and that fuller picture was probably never put in front of you. You walked out with a clean bill of health and a clock running that nobody was reading.

Because here is what is happening inside you right now, whether you measure it or not. From roughly mid-adulthood, kidney filtration tends to decline gradually. In healthy adults, studies estimate an average decline of around 0.4 to 1.1 mL/min/1.73 m² per year, though the slope varies widely from person to person. The tiny filters that do the work, the nephrons, do not grow back. By the time a doctor says "chronic," you are decades into a slide you were never tracking. And it does not stay in your kidneys. Failing kidneys pump inflammation through your whole body and pull your heart attack risk up behind them.

The kidney is the canary, the coal mine, and the gas leak. All at once. And the standard system is built to notice only after the cliff.

One of the highest-leverage discussions you can have with your physician is often inexpensive, and I am giving you the framework in full, right here.

Ask your physician about three things at your next blood draw. Cystatin C. A standard creatinine and eGFR panel. And a urine albumin-to-creatinine ratio. This is not an exotic longevity panel. These are standard, accessible kidney-risk tests your physician can order, and together they can surface accelerating kidney aging earlier than a routine physical.

How to read them, which almost no one tells you. Cystatin C adds a second view, because it is much less dependent on skeletal muscle than creatinine. The urine albumin test catches a different failure, protein leaking through the filter, that the blood tests can miss. And the decisive habit is to track the trend across two or three years, not a single reading. One number is noise. A slope bending the wrong way is one of the earliest signals you can get that your whole-body aging may be accelerating. Take that trend to your physician, and if it is bending, that is the conversation where your physician may evaluate blood pressure, metabolic health, and whether additional interventions are appropriate. That is a clinical decision, not a newsletter's to make.

Do that this quarter. I am doing it myself. It is inexpensive, it is accessible, and the trend it reveals matters more than any single company in this letter.

Here is the part that should land hardest for the reader who is already doing the work.

If you are 45 or older and already doing the work, you have probably focused on your heart. You may know your ApoB, the number that tracks the particles driving heart disease, along with your blood pressure, glucose, and inflammation markers, and you may be managing them with the tools we now have. That is the right fight. Cardiovascular disease remains one of the biggest threats to a long life.

But kidney decline is one reason cardiovascular risk can quietly reappear even when the lipid plan looks disciplined.

When kidney function declines, the damage does not stay in the kidney. CKD is linked with higher cardiovascular risk through several routes at once: blood pressure, chronic inflammation, vascular calcification, fluid balance, anemia, mineral metabolism, and changes in lipoprotein metabolism. The lipid pattern in kidney decline is often different from ordinary cholesterol risk, higher triglycerides, lower HDL, altered lipoprotein quality, and in some patients a higher burden of ApoB-containing particles.

That does not mean kidney decline automatically overwhelms a good lipid plan, and it does not mean ApoB-lowering therapy stops working. What it means is that the kidney is an upstream organ in cardiovascular aging, and if you are serious about longevity, it deserves a place beside ApoB, blood pressure, glucose, and body composition. The heart may be the organ people fear most. The kidney may be one of the organs quietly deciding whether your cardiovascular plan holds.

So if the floor is a simple, accessible blood-and-urine panel, what is the ceiling? What would it take to not just monitor the decline, but reverse it?

That is where, for decades, the kidney industry leaned one way. Much of it has historically focused on diagnosed CKD: slowing progression, dialysis, transplant, end-stage failure. Far less has been built for the slow, preclinical decline that pushes otherwise healthy people toward that edge. If you are a healthy 50-year-old who simply wants to keep the kidneys you have, there is strikingly little aimed squarely at you.

That is the villain of this story. Not a company. An industry that only knows how to treat the disaster, never the decline.

But that is finally changing, and it is changing across several mechanisms at once, the SpaceX-style alignment:

For the first time, there are real companies, with real backers and real data, working directly on the kidney. Five of them, the ones actually building kidney-specific medicine, are what I want to walk you through. Below the line, I will give you all five by name, exactly where each scored, and the precise trigger that would move each one higher on my watchlist.

The floor is free. The map of where the money and the science are going is for members, because its entire value is being early.

Below the line you get the full research tracker entry for this issue:

Most of these companies are private, early-stage, and inaccessible to many investors today. The value here is understanding the field before it becomes widely followed, not acting on any single name.

If you are reading the free version, this is the issue where the watching starts. You do not want to meet these five the morning after the world notices.

[ Become a member and unlock all five tracker companies, their scores, and their triggers. Cancel inside 7 days and pay nothing. Annual members lock in today's rate. ]